DUBLIN--(BUSINESS WIRE)--The "Bacterial Vaginosis - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Bacterial Vaginosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Bacterial Vaginosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bacterial Vaginosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Bacterial Vaginosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Report Coverage
- Bacterial Vaginosis - Overview
- Bacterial Vaginosis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Bacterial Vaginosis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bacterial Vaginosis - Companies Involved in Therapeutics Development
- Evofem Biosciences Inc
- Melinta Therapeutics Inc
- Osel Inc
- Pharmiva AB
- Profarma
- Starpharma Holdings Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/t6drm9/bacterial?w=4
